Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

4.020 -0.040 (-0.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,887
Open 3.980
Bid (Size) 4.000 (16)
Ask (Size) 4.060 (1)
Prev. Close 4.060
Today's Range 3.870 - 4.060
52wk Range 3.210 - 8.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
From Coya Therapeutics, Inc.
Via Business Wire
How The Same Treatments May Work For Multiple Neurodegenerative Diseases
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate. 
Via Talk Markets

Performance

YTD
-13.55%
-13.55%
1 Month
+13.88%
+13.88%
3 Month
-11.65%
-11.65%
6 Month
+0.75%
+0.75%
1 Year
-12.04%
-12.04%

More News

Read More
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases
From Coya Therapeutics, Inc.
Via Business Wire
Analyst Expectations for Coya Therapeutics's Future
Via Benzinga
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023
From Coya Therapeutics, Inc.
Via Business Wire
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors
From Coya Therapeutics, Inc.
Via Business Wire
The Latest Analyst Ratings for Coya Therapeutics
Via Benzinga
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation
Via Benzinga
Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth
Via Benzinga
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC)
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease
Via Get News
Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.